Pathological Assessment for Clinical Trials of Non-Alcoholic Fatty Liver Disease
1. Abstract Non-Alcoholic Fatty Liver Disease (NAFLD) has increasingly become a common cause of liver cirrhosis, hepatocellular carcinoma, and liver-related death. Currently, there are no therapeutic drugs that have proven efficacy and safety through randomized controlled clinical trial.